From the 17th International Workshop on Non-Hodgkin Lymphoma held in Boston, MA, John Gribben, MD, of Barts Cancer Institute, London, UK, and Jay Bradner, MD, President of Novartis Institutes for BioMedical Research, Cambridge, MA, discuss the need for academic and pharmaceutical collaboration to advance treatments for patients. Dr Bradner also describes the process of research and development at Novartis, emphasizing its similarities with academia.
